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Abstract 
Background: Falcipains are major cysteine proteases of Plasmodium falciparum involved in haemoglobin degrada-
tion and remain attractive anti-malarial drug targets. Several inhibitors against these proteases have been identified, 
yet none of them has been approved for malaria treatment. Other Plasmodium species also possess highly homolo-
gous proteins to falcipains. For selective therapeutic targeting, identification of sequence and structure differences 
with homologous human cathepsins is necessary. The substrate processing activity of these proteins is tightly 
controlled via a prodomain segment occluding the active site which is chopped under low pH conditions exposing 
the catalytic site. Current work characterizes these proteases to identify residues mediating the prodomain regulatory 
function for the design of peptide based anti-malarial inhibitors.
Methods: Sequence and structure variations between prodomain regions of plasmodial proteins and human 
cathepsins were determined using in silico approaches. Additionally, evolutionary clustering of these proteins was 
evaluated using phylogenetic analysis. High quality partial zymogen protein structures were modelled using homol-
ogy modelling and residue interaction analysis performed between the prodomain segment and mature domain to 
identify key interacting residues between these two domains. The resulting information was used to determine short 
peptide sequences which could mimic the inherent regulatory function of the prodomain regions. Through flexible 
docking, the binding affinity of proposed peptides on the proteins studied was evaluated.
Results: Sequence, evolutionary and motif analyses showed important differences between plasmodial and human 
proteins. Residue interaction analysis identified important residues crucial for maintaining prodomain integrity across 
the different proteins as well as the pro-segment responsible for inhibitory mechanism. Binding affinity of suggested 
peptides was highly dependent on their residue composition and length.
Conclusions: Despite the conserved structural and catalytic mechanism between human cathepsins and plasmodial 
proteases, current work revealed significant differences between the two protein groups which may provide valuable 
information for selective anti-malarial inhibitor development. Part of this study aimed to design peptide inhibitors 
based on endogenous inhibitory portions of protease prodomains as a novel aspect. Even though peptide inhibitors 
may not be practical solutions to malaria at this stage, the approach followed and results offer a promising means to 
find new malarial inhibitors.
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Background
Malaria, caused by parasites from the genus Plasmo-
dium and transmitted to human by a female anopheles 
mosquito bite, remains a major public health menace 
with an estimated annual rate of 0.45 million fatalities 
[1]. Parallel to evolving mosquito resistant to insecti-
cides [1–4], continuously emerging resistant strains of 
parasite to current drugs [5–8] present an immense 
challenge for the eradication of malaria. A recent study 
promisingly showed that pre-existing resistance may 
not be a major problem for novel target anti-malarial 
candidates, and fast-killing compounds may result in a 
slower onset of clinical resistance [9]. Hence, the iden-
tification and development of alternative anti-malarial 
inhibitors with novel mode of action against new as 
well as known drug targets is crucial.
Proteases are considered as good parasitic drug tar-
gets and details are presented in a number of articles 
[10–16]. Cysteine proteases have a central role in Plas-
modium parasites during haemoglobin degradation [17, 
18], tissue and cellular invasion [19], activation of pro-
enzymes [20, 21], immunoevasion and egression [11, 
21, 22]. Red blood cell (RBC) invasion and rupturing 
processes as well as intermediate events involving hae-
moglobin metabolism are characterized by increased 
proteolytic activity. During the asexual intraerythro-
cytic stage, Plasmodium parasites degrade nearly 75% 
of host RBC haemoglobin [23, 24] to acquire nutrients 
as they lack a de novo amino acid biosynthetic pathway. 
By this process, they can acquire all their amino acid 
requirements necessary for growth and multiplication 
with an exception of isoleucine which is exogenously 
imported as it is absent in human haemoglobin [10, 25, 
26]. Haemoglobin degradation is an intricate and effi-
cient multistage protein catabolic process occurring 
inside the acidic food vacuole [18, 27].
This study focuses on a subgroup of papain-like Clan 
CA plasmodial cysteine proteases, namely falcipains 
(FPs) of Plasmodium falciparum and their homologs. 
Plasmodium falciparum has four FPs; FP-1, FP-2, FP-2’ 
and FP-3. FP-1 is the most conserved protease among 
the four proteases, and its role in parasite entry into 
RBCs is yet to be resolved. Although its inhibition 
using specific peptidyl epoxides blocked erythrocyte 
invasion by merozoites [28], FP-1 gene disruption in 
blood stage parasites does not affect their growth [29, 
30]. Despite its biological function remaining uncer-
tain, FP-2′ is biochemically similar to FP-2 and shares 
99% sequence identity [22, 31]. FP-2 (FP-2′) and FP-3 
share 68% sequence identity and are the major cysteine 
proteases involved in haemoglobin degradation in the 
parasite [32–35]. Expression of these proteins during 
the blood stage by plasmodia is strictly regulated in a 
site-specific and time-dependent manner [28, 36, 37]. 
These haemoglobinases have differential expression 
timing during the trophozoite stage: the early phase is 
characterized by FP-2 abundance while FP-3 is abun-
dant at the late stages [17, 22]. It was shown that tar-
geted disruption of FP-2 gene in Plasmodium results 
in accumulation of undigested haemoglobin in the 
food vacuole and its enlargement [17], therefore, the 
protein can be considered as a promising drug target 
[38, 39]. On the other hand, inhibiting individual pro-
teases might not be essential due to redundancy in the 
haemoglobin digestion stage [10], hence any inhibitor 
design for FPs should consider blocking the activity of 
both FP-2 and FP-3. The importance of FP-2 as a drug 
target was also indicated in a recent study in which 
FP-2 polymorphisms were shown that are associated 
with artemisinin resistance [40].
Other Plasmodium species also express proteins 
highly homologous to FP-2 and FP-3 [41–44]. These 
include vivapains (vivapain 2 [VP-2] and vivapain 3 
[VP-3]), knowlesipains (knowlesipain 2 [KP-2] and 
knowlesipain 3 [KP-3]), berghepain 2 [BP-2], chabau-
pain 2 [CP-2] and yoelipain 2 [YP-2] from Plasmodium 
vivax, Plasmodium knowlesi, Plasmodium berghei, 
Plasmodium chabaudi and Plasmodium yoelii, respec-
tively. All these proteins are related both in sequence 
and function to the papain-like class of enzymes includ-
ing human cathepsins. The plasmodial proteases have, 
however, unusual features compared to the human 
ones including, much longer prodomains and specific 
inserts in the catalytic domain—a “nose” (~ 17 amino 
acids) and an “arm” (~ 14 amino acids) [37, 45, 46]. In 
native environment, cysteine proteases are regulated 
either by their prodomain (zymogen form) or by other 
endogenous macromolecules like cystatins [47, 48] and 
chagasin [49]. During erythrocyte entry, P. falciparum 
secrete falstatin, a potent picomolar inhibitor of both 
FP-2 and FP-3 thus regulating the activity of these pro-
teases on important surface proteins required for inva-
sion [19, 48]. In the zymogen form (Fig.  1), a part of 
the prodomain flips over the active pocket and its sub-
sites located on the catalytic domain [50], blocking its 
enzyme activity [51]. The acidic environment within a 
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food vacuole (Plasmodium) or lysosome (humans) trig-
gers prodomain cleavage thus activating the catalytic 
domain [52, 53].
The literature comprises a large number of inhibitors 
against FPs derived from both experimental and compu-
tational approaches. The identified inhibitors, which are 
either synthetic or from natural sources, fall into three 
main categories: peptide-based [31, 54–56], non-peptidic 
[50, 57–61]; and peptidomimetic [58, 62, 63]. Majority of 
the peptidic and peptidomimetic inhibitors have shown 
activity against FPs at nanomolar concentrations. So far, 
the strongest potency ranging from nanomolar to pico-
molar concentrations has been reported from a series of 
2-pyrimidine cabornitriles derivatives [58]. Application 
of computer assisted drug design (CADD) approaches 
as well as virtual screening strategies have also been uti-
lized to identify novel non-peptidic FP compounds [57, 
64]. Molecular dynamics approaches as well as binding 
free energy calculations have also been employed to deci-
pher the atomic interaction details and stability of pro-
tein–ligand complexes [50, 57]. Hitherto, none of these 
inhibitors has been approved as an anti-malarial drug 
as they have limited selectivity against host cathepsins, 
homologs to the parasites proteases. To overcome this, 
distinctive features between these two classes of proteins 
must be determined.
The current work utilizes in silico approaches to char-
acterize FP-2 and FP-3 and their homologs from other 
Plasmodium species as well as human homologs (cath-
epsins) to identify sequence, physicochemical and 
Fig. 1 Clan CA cysteine protease zymogen prodomain-catalytic domain interaction modes. Surface representation of a human Cat-K and b FP-2. 
c FP-2 prodomain structural elements (pink; in cartoon representation) interacting with the S1 (red), S2 (blue), S3 (green) and S1′ (cyan) subsites of 
the catalytic domain
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structure differences that can be exploited for peptide-
based anti-malarial drug development. Although the two 
protein classes share high similarity, important differ-
ences that can be essential for inhibitor selectivity exist 
[50, 65]. The main aim of this study is to elucidate the 
inhibitory mechanism of plasmodial prodomain region 
responsible for endogenous regulation of the catalytic 
domain, information which may be useful in the design 
of novel peptide-based inhibitors. For this purpose, using 
domain–domain interaction approaches, specific hot 
spot residues critical for the mediation of the prodomain 
inhibitory effect were identified. To further identify a 
potential peptide segment, which could strongly bind to 
the plasmodial catalytic domains and mimic the native 
prodomain inhibitory effect, five short peptide sequences 
based on the identified hot spot residues were suggested. 
Flexible docking of these peptides against the catalytic 
domains identified a short 13-mer oligopeptide with 
preferential binding towards plasmodial proteases. This 
oligopeptide could be a starting platform for the devel-
opment and testing of novel peptide based anti-malarial 
therapies against plasmodial cysteine proteases. It is 
known that the use of peptides for treatment of malaria 
faces a myriad of challenges mainly due to low perme-
ability, metabolic instability, short half-life, low oral bio-
availability and limited residence time in tissues [66, 67]. 
Nonetheless, several in vitro and in silico strategies have 
been established to enhance peptide developability as 
drugs [68, 69]. Currently, the use of nanotechnology for 
site specific drug delivery systems to increase bioavail-
ability continues to be explored and may soon offer a 
breakthrough in the application of anti-malarial peptides 
[70–72].
Methods
A workflow consisting of the different methods, tools and 
databases used in this study is shown in Fig.  2. Unless 
otherwise indicated, amino acid numbering is based on 
individual protein full length as listed in Additional file 1.
Sequence retrieval and multiple sequence alignment
Using FP-2 (PF3D7_1115700) and FP-3 (PF3D7_1115400) 
as query sequences, seven plasmodial protein homologs 
together with three human homologs (Table  1) were 
retrieved from the PlasmoDB version 9.31 [73] and NCBI 
[74] databases, respectively as described earlier [50]. A 
pronounced feature present in the cathepsin L (Cat-L) 
like plasmodial proteases is the presence of an N-termi-
nal signalling (non-structural) peptide sequence (~ 150 
amino acids), which is responsible for targeting them 
into the food vacuole. For each of the plasmodial pro-
teins, this segment was chopped off, and the remaining 
prodomain portion-catalytic domain saved into a Fasta 
file (Additional file 2). As guided by the partial zymogen 
complex crystal structure of Cat-K [PDB: 1BY8], ~ 21 
amino acids (N-terminal) were also chopped off from 
the human cathepsin prodomain sequences. Together, 
these sequences were used in the rest of the study, and 
are referred as “partial zymogen” or “prodomain-catalytic 
domain” sequences interchangeably in the manuscript. 
Position details of the prodomain and catalytic portions 
per protein are listed in Additional file  1. To determine 
Fig. 2 A graphical workflow of the methods and tools (in brackets) used in sequence and structural analysis of FP-2, FP-3 and their homologs
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the conservation of the prodomain-catalytic portion, 
multiple sequence alignment (MSA) was performed 
using PROfile Multiple Alignment with predicted Local 
Structures and 3D constraints (PROMALS3D) web 
server [75] with default parameters except PSI-BLAST 
Expect value which was adjusted to 0.0001, and the align-
ment output visualized using JalView [76].
Phylogenetic inference
Using Molecular Evolutionary Genetic Analysis (MEGA) 
version 5.2 software [77], the evolutionary relation-
ship of plasmodial proteases and human cathepsins was 
evaluated with the following preferences; Maximum 
Likelihood (statistical method) and Nearest-Neighbor-
Interchange (NNI) as the tree inference option. A total 
of 48 amino acid substitution models were calculated for 
both complete (100%) and partial (95%) deletion and the 
best three models based on Bayesian Information Cri-
terion (BIC) were selected (Additional file  3). For each 
selected model, the corresponding gamma (G) evolu-
tionary distance correction value was selected to build 
different phylogenetic trees and comparison was made 
to determine robustness of dendrogram construction 
process. Toxoplasma gondii Cat-L [NCBI accession num-
ber: ABY58967.1] was included in the tree calculations as 
outgroup.
Physicochemical properties
Using an ad hoc Python and Biopython script, the amino 
acid composition and physicochemical properties, 
namely molecular weight (Mr), isoelectric point (pI), aro-
maticity, instability index, aliphatic index and grand aver-
age of hydropathy index (GRAVY) of the proteins were 
determined.
Motif analysis
Multiple Em for Motif Elicitation (MEME) standalone 
suite version 4.10.2 [78] was used to identify the com-
position and distribution of protein motifs within partial 
zymogen sequences. A Fasta file (Additional file 2) con-
taining sequence information of the different proteins 
was parsed to MEME software with analysis preferences 
set as; -nostatus –time 18,000 –maxsize 16,000 –mod 
zoops –nmotifs X –minw 6 –maxw 50. The variable X (a 
whole number from 1) was varied until no more unique 
motifs were assessable as determined by Motif Alignment 
Search Tool (MAST) [79]. A heat map showing motif dis-
tribution was generated using an in house Python script. 
PyMOL was used to map the different motifs onto the 
protein structures (The PyMOL Molecular Graphics Sys-
tem, Version 1.6.0.0 Schrödinger, LLC).
Homology modelling and structure validation
MODELLER version 9.18 [80] was used to build homol-
ogy models of the inhibitor complex of all proteins except 
for Cat-K which has already a crystal structure. Using a 
combination of templates, high quality prodomain-cat-
alytic domain complexes of the plasmodial proteases as 
well as cathepsins (Cat-L and Cat-S) were calculated by 
MODELLER with refinement set to very slow. Additional 
file  4 shows the details of templates selected for each 
protein model. For the plasmodial proteases, the crys-
tallographic structure of procathepsin L1 from Fasciola 
hepatica [PDB: 2O6X] was used as it had the highest sim-
ilarity with most target sequences (30–38%) and high res-
olution of 1.40 Å. However, it lacked the arm (β-hairpin) 
region while the nose residues were missing. To over-
come these challenges, Cat-K [PDB: 1BY8] together with 
FP-2 [PDB: 2OUL] (for FP-2, VP-2, KP-2, BP-2 and YP-2) 
Table 1 Details of all protein sequences retrieved from PlasmoDB and NCBI databases
Percentage sequence identity (SI) is calculated based on the partial zymogen of query sequence (QS) and that of corresponding homolog
a FP-2 homolog, bFP-3 homolog
Source organism Host Accession number Common name (abbreviation) aa % SI
P. falciparum (Pf ) Human PF3D7_1115700 Falcipain-2 (FP-2) 484 QS
PF3D7_1115400 Falcipain-3 (FP-3) 492 QS
P. vivax (Pv) PVX_091415 Vivapain-2 (VP-2) 487 56a
PVX_091410 Vivapain-3 (VP-3) 493 55b
P. knowlesi (Pk) Human/monkey PKH_091250 Knowlesipain-2 (KP-2) 495 53a
PVX-091260 Knowlesipain-3 (KP-3) 479 58b
P. yoelii (Py) Rodents PY00783 Yoelipain-2 (YP-2) 472 47a
P. chabaudi (Pc) PCHAS_091190 Chabaupain-2 (CP-2) 471 48b
P. berghei (Pb) PBANKA_093240 Berghepain-2 (BP-2) 470 50a
H. sapiens – NP_000387.1 Cathepsin-K (Cat-K) 329 34a
AAA66974.1 Cathepsin-L (Cat-L) 333 33a
AAC37592.1 Cathepsin-S (Cat-S) 331 32a
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and FP-3 [3BWK] (for FP-3, VP-3, KP-3 and CP-2) were 
additionally used. For Cat-L and Cat-S, only two tem-
plates were used [PDB: 1BY8 and 2O6X]. For each pro-
tein, 100 models were calculated and ranked according to 
normalized discrete optimized protein energy (Z-DOPE) 
score [81]. The top three models per protein were fur-
ther validated using ProSA [82], Verify3D [83], QMEAN 
[84] and PROCHECK [85] and the best quality model 
selected.
Prodomain‑catalytic domain interaction studies 
and short inhibitor peptide design
To determine the prodomain inhibitory mechanism, 
residue interactions between prodomain and catalytic 
domain of plasmodial and human partial zymogen com-
plexes were evaluated using the Protein Interaction Cal-
culator (PIC) web server [86]. The interaction energy 
of identified residues was evaluated using the amino 
acid interaction (INTAA) web server [87]. PyMOL was 
used to visualize the resulting interactions. For each 
protein, prodomain segment interacting with the cata-
lytic domain’s active pocket residues was identified and 
extracted into a Fasta file. From the interaction ener-
gies, residues within these inhibitory segments forming 
strong contacts with subsite residues were identified. 
Based on the identified hot spot residues, the next objec-
tive was to design short peptide(s) exhibiting the native 
prodomain effect whilst showing selectivity on human 
cathepsins. The conservation of prodomain inhibitory 
segments for all the proteins, and separately of only the 
plasmodial proteases, was determined using WebLogo 
server [88]. Peptides of varying lengths and composition 
based on amino acid conservation forming contacts with 
subsite residues were proposed. In order to evaluate the 
interaction of selected peptides on the catalytic domains, 
the prodomain segments of all proteins were chopped 
using PyMOL. Blind docking simulation runs of selected 
peptides were then performed on these sets of catalytic 
domains by CABS-dock protein-peptide docking tool 
[89] using the default parameters. To confirm the reli-
ability of the results, docking experiments were repeated 
using catalytic domains of the same proteins that had 
been modelled and used in previous studies [50]. Binding 
affinity (ΔG) and dissociation constant  (Kd) for each pro-
tein-peptide complex was then evaluated using PROtein 
binDIng enerGY prediction (PRODIGY) web server [90].
Results and discussion
This work is presented in two main parts: The first part 
analyses the proteins of interest in sequence level via 
physicochemical properties calculations, MSA, phy-
logenetic tree calculations and motif analysis with the 
aim of understanding the general differences between 
plasmodial proteins and human cathepsins. Part 2 starts 
to use the sequence differences identified in Part 1 at 
structural level with further analysis on residues that are 
involved in the regulation of the catalytic domain per 
protein with an aim of designing short peptides which 
could mimic the prodomain segment inhibitory mecha-
nism. While Part 1 relies on sequence information, Part 
2 requires good quality structural information. Here, 3D 
structures of partial zymogens are calculated via homol-
ogy modelling. Accuracy of these models is checked 
with a range of validation tools that gave consistently 
high quality scores for the selected models (Table  2). 
QMEAN results showed that only small portions of the 
loop regions in Cat-L, Cat-S, and CP-2 were of poor qual-
ity, while the majority of the prodomain-catalytic core 
regions in all of the proteins was accurate (Fig.  3 and 
Additional file 5). As these loop regions were far from the 
catalytic pocket, the resulting models were considered 
acceptable for further analysis.
Both plasmodial and human cathepsins have similar 
physicochemical properties
Protein function is largely governed by its structure, 
amino acid composition as well as its environment. 
Despite the low sequence identity between the two sub-
classes (cathepsins and plasmodial proteases), phys-
icochemical analysis revealed that they have similar 
aromaticity and grand average hydropathy (GRAVY) 
values indicating that both groups of proteins are hydro-
philic (Table 3). With an exception of CP-2, all the other 
proteins have an instability index score of ≤ 40 and thus 
can be considered as being stable in test-tube environ-
ment [91]. Interestingly, there is no significant differ-
ence between the aromaticity, GRAVY and instability 
index scores of partial zymogen complex and individual 
catalytic domains either. However, significant differ-
ences exist in the molecular weight and isoelectric point 
(pI). Plasmodial partial zymogens have higher molecu-
lar weight than that of human cathepsins, as they have 
longer sequences (two additional structural catalytic 
domain inserts and longer prodomains). A key factor that 
controls the functioning of cysteine proteases is pH of the 
milieu in which they are found. All the plasmodial prodo-
main-catalytic complexes and Cat-L have a slightly acidic 
pI of 5.66 ± 0.37 with their catalytic domains exhibiting 
lower pI. The other cathepsins have basic pI for both 
their partial zymogen complexes and catalytic domains. 
This difference in pI profiles might explain the localiza-
tion aspects of these proteins where the plasmodial pro-
teases and Cat-L are found in acidic food vacuoles and 
lysosomes, respectively while the remaining cathepsins 
are predominantly found in extracellular matrix.
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Plasmodial clan CA proteases and human cathepsins 
exhibit separate evolutionary clustering
In addition to the previous findings for catalytic domain 
conservation discussed comprehensively in [50], cur-
rent MSA identified two highly conserved ERFNIN and 
GNFD motifs, which are located in the α2-helix and 
the adjacent downstream loop region between β turn 
and α3-helix, respectively (Figs.  1 and 4). Despite the 
highly conserved nature of the ERFNIN motif across 
all the plasmodial proteins studied, FP-2 and CP-2 have 
Val residue in the place of Ile196 (numbering based on 
FP-2). In the human cathepsins, the motif ’s Phe190 (FP-2 
Table 2 Homology model quality validation scores of partial zymogen complexes using different assessment tools
* Template
Protein Z‑DOPE Verify3D ProSA QMEAN RAMACHANDRAN (%)
Favoured Allowed Disallowed
FP-2 − 1.05 78.48 − 8.27 0.69 88.90 10.50 0.60
FP-3 − 0.94 84.64 − 7.84 0.67 89.70 10.30 0.00
VP-2 − 0.64 81.27 − 6.94 0.62 85.40 13.90 0.70
VP-3 − 0.74 79.58 − 7.31 0.70 88.60 11.40 0.00
KP-2 − 0.63 85.89 − 7.23 0.62 89.30 9.70 1.00
KP-3 − 0.92 90.63 − 7.88 0.63 86.10 13.90 0.00
BP-2 − 0.62 86.85 − 7.75 0.63 86.60 12.40 1.00
CP-2 − 0.60 84.45 − 7.02 0.63 83.90 13.80 2.30
YP-2 − 0.42 75.54 − 7.28 0.62 84.90 14.40 0.70
Cat-L − 1.47 87.38 − 7.94 0.87 89.80 9.80 0.40
Cat-S − 1.61 85.39 − 8.57 0.79 89.20 10.40 0.20
1BY8 * 85.16 − 8.62 0.78 65.80 34.20 0.00
2O6X * 94.77 − 7.00 0.77 90.50 9.50 0.00
2OUL * 98.13 − 7.90 0.75 88.10 11.20 0.70
3BWK * 93.51 − 7.35 0.65 86.10 13.30 0.60
Fig. 3 Homology models of different plasmodial proteases and human Cat-L together with the templates used in homology modelling. Colour 
code ranges from blue (accurate modelling) to red (poorly modelled regions)
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Table 3 A summary of physicochemical properties of FP-2 and FP-3 and homologs partial zymogen sequences
a Significant variation between partial zymogen and catalytic sequence
Protein Aromaticity GRAVY Instability index Mwgta pIa
Complex Catalytic Complex Catalytic
FP-2 0.12 − 0.59 40.31 38,021.06 27,176.69 6.50 4.94
FP-3 0.14 − 0.53 33.90 38,029.91 27,348.62 5.47 4.72
VP-2 0.14 − 0.40 23.78 37,941.11 27,388.93 5.49 4.74
VP-3 0.14 − 0.47 28.92 38,405.76 28,088.95 5.60 5.00
KP-2 0.14 − 0.54 29.55 38,583.83 27,947.73 5.69 4.93
KP-3 0.14 − 0.51 23.16 38,284.39 27,685.36 5.89 5.13
BP-2 0.14 − 0.52 39.73 38,014.94 27,367.90 5.44 4.77
CP-2 0.13 − 0.47 52.14 37,883.92 27,140.51 5.14 4.54
YP-2 0.14 − 0.46 40.05 38,120.25 27,454.06 5.66 4.78
Cat-K 0.10 − 0.62 33.12 34,566.05 23,495.47 8.83 8.92
Cat-L 0.13 − 0.70 38.17 35,074.20 24,298.86 5.33 4.64
Cat-S 0.12 − 0.56 37.20 34,986.63 23,963.97 8.44 7.64
Fig. 4 Structural-based multiple sequence alignment of FP-2, FP-3 and homologs prodomain-catalytic domains. Actual residue numbering per 
protein is given on the side, and the top numbering is based on partial zymogen alignment. The papain family characteristic prodomain ERFNIN 
and GNFD motif residues are indicated with an asterisk. Bold short lines depict the prodomain-catalytic domain border. Dashed green lines indicate 
the position of α-helix and arrows β-sheet structural elements. Fully conserved residues in all the proteins are marked with red while residues 
only conserved in plasmodial proteases with blue. Position of subsite residues is shown with filled circles (Red = S1, Blue = S2, Green = S3 and 
S1′ = black)
Page 9 of 21Musyoka et al. Malar J          (2019) 18:159 
numbering) is replaced by a Trp, a more hydropho-
bic residue. Using site-directed mutagenesis, Kreusch 
et  al. identified two additional conserved Trp residues 
in human Cat-L (position 29 and 32 in Cat-L full length 
protein) which together with the highly conserved motifs 
(ERFNIN and GNFD) are important in the stability of the 
partial zymogen complex [92]. In plasmodial proteases, 
conservative substitution occurs on these two residues 
whereby they are replaced by less hydrophobic Phe resi-
dues (position 165 and 169 in FP-2). The contribution of 
these amino acid variations will be further discussed in 
the “Prodomain regulatory effect mediated by α3 helix 
hydrophobic interactions with subsites S2 and S1’ resi-
dues” section. MSA result also revealed that cathepsins 
have a three amino acid insert in the α2 helix between the 
ERFNIN/GNFD motifs which is absent in the plasmodial 
proteases, and its importance is yet to be reported.
Phylogenetic analysis using partial zymogen sequences 
gave a distinct clustering between plasmodial proteins 
and human cathepsins forming two separate clades 
(Fig.  5). There is no notable difference in tree topology 
in analysis performed using the catalytic domains only. 
This can be explained by the observed low sequence 
identity in both partial zymogen (Table  1) and catalytic 
domain sequences between the two groups of proteins 
[50]. The plasmodial proteases further clustered into two 
main subgroups based on the host. This is attributed to 
the previously reported sequence variations between the 
human and rodent plasmodial proteases [50]. FP-2 and 
FP-3 forms a separate sub-group from the other human 
plasmodial proteases possibly due to the high sequence 
similarity between the two proteins. The rate of mutation 
accumulation appears to vary between the two classes 
of proteins, being slowest in the human cathepsins. All 
human plasmodial proteases seem to evolve at the same 
rate as compared to the rodent orthologs which appear to 
show the highest substitution rate among all the proteins.
Plasmodial proteases have unique motifs compared 
to human cathepsins
Sequence motifs within proteins might be associated 
with a specific biological function. Thus to better under-
stand and characterize a group of proteins, identifica-
tion of common and distinguished motifs is of critical 
importance. A total of 13 unique motifs with varied dis-
tributions were identified in the set of proteins studied 
(Fig.  6a). These motifs were then mapped onto the 3D 
structures of partial zymogen complexes (Fig. 6b, c). Five 
motifs (M1, M3, M5, M6 and M7) are present in both 
the plasmodial and human proteases. Out of these five 
motifs, M1, M3, M5 and M7 are located at the catalytic 
domain of all proteins while M6 is at α3-helix region of 
Fig. 5 A phylogenetic tree of plasmodial and human FP-3, and FP-3 homologs prodomain-catalytic protein sequences using MEGA5.2.2. The 
evolutionary history was inferred by using the Maximum Likelihood method based on the Whelan and Goldman model (WAG) model with a γ 
discrete distribution (+G) parameter of 2.4 and an evolutionary invariable ([+I]) of 0.1. All positions with gaps were completely removed (100% 
deletion) and bootstrap value set at 1000. The scale bar represents the number of amino acid substitutions per site. Toxoplasma gondii CAT-L is used 
as the outgroup
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the prodomain (Fig. 6b, c). Up to three motifs; M2, M4 
(located in α1-helix) and M8 (nose region) are only found 
within the plasmodial proteases, except FP-2 lacks M8. A 
differential motif composition of the anterior prodomain 
region (α1- α3 helix) of the two classes of proteins was 
observed with one long motif (M4) in plasmodial pro-
teases while human cathepsins have two (M10 and M12).
PROSITE [93] and MyHits [94] webservers were used 
to search for the functional importance of identified 
motifs. M1 (PF00112.15) is the peptidase_C1 functional 
site and consists of PS00139 (QQnCGSCWAfST-cysteine 
protease active site), PS00008 (GVvesSQ-N-myristoyla-
tion site), and PS00006 (casein kinase II phosphoryla-
tion site). M2 (PF00112) is a characteristic functional site 
of papain-like family cysteine proteases located at the 
Fig. 6 Motif analysis of plasmodial proteases and human cathepsins partial zymogen domains. a A heat map showing the distribution, level of 
conservation and information of different motifs found in plasmodial and human proteases studied. A cartoon presentation showing the location of 
all motifs within the prodomain-catalytic structural fold. Labelled in green boxes are motifs present in both (b) human cathepsins and (c) plasmodial 
proteases
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C- terminus (α7-helix to β4), and forms part of the arm 
region of plasmodial proteases. M3 is located in α6-helix, 
and the adjacent loop regions of all the Clan CA group of 
enzymes have no function assigned to it. M4 (PF08246) 
is known as the cathepsin propeptide inhibitor domain 
(Inhibitor I29), and is located at α1 and α2 helixes of the 
N-terminus. The other motifs had no defined function 
assigned to them according to these webservers.
Prodomain regulatory effect mediated by α3 helix 
hydrophobic interactions with subsites S2 and S1′ residues
Different non-canonical interactions were identified 
between the prodomain and catalytic domain of proteins. 
These included hydrophobic, cation-π, ionic, aromatic–
aromatic and hydrogen bonds. In all partial zymogen 
complexes studied, no disulphide linkages between the 
two domains were observed. The main interactions 
exhibited are hydrophobic and hydrogen bonds, which 
participated either in anchoring and maintaining the 
folding integrity of the prodomain segment, or in medi-
ating its inhibitory effect by interacting with subsite 
residues (Additional file  6). Residue interaction results 
revealed that prodomain anchoring residues are located 
on the region between α1-helix and the β-turn which 
interacted with β3 and part of the arm region in the cata-
lytic domain (Figs. 4, 7). Additionally, the C-terminus of 
the prodomain interacts with the N-terminus of the cata-
lytic domain and residues within α7-β3 segment (Fig. 4). 
For anchoring of the prodomain inhibitory segment in 
plasmodial proteases, a network of hydrogen bonds and 
hydrophobic interactions (bond order < − 10  kJ/mol) 
between His199-Asp398, Tyr207-Asp408 and Lys208-
Glu404 (FP-2 numbering) occurred in all plasmodial 
proteins (Fig.  7a). These residues were only conserved 
in the plasmodial proteases. In the cathepsins, although 
such a highly conserved network is missing as observed 
in plasmodial proteins, the number of anchoring resi-
dues seemed to be more than in the plasmodial pro-
teases. A strong hydrogen and hydrophobic interaction 
network running from the N-terminal end to the GNFD 
motif prodomain residues, possibly for maintaining its 
structural fold, was identified in all proteins (Fig.  7). In 
comparison with the human cathepsins, the plasmodial 
proteases had longer N-terminal prodomain regions 
(Fig. 4) harbouring a series of highly conserved residues 
viz. Met156, Asn158, Glu160 and Asn163 (FP-2 number-
ing). These residues formed a hydrophobic interaction 
network with bonds of the order < − 10.0  kJ/mol with 
neighbouring residues (Fig. 7). Two additional aromatic–
aromatic interactions between Phe165-Phe168 and 
Tyr166-Phe189 (FP-2 numbering) in all the plasmodial 
proteases formed strong bonds with energies less than 
Fig. 7 Intra-prodomain and prodomain-catalytic residue interaction network in a FP-2 and b Cat-K. For each protein full length residue numbering 
is used. Enclosed in black are residue interactions involved in anchoring the prodomain onto the catalytic domain with the rest being those 
involved in mediating the inhibitory effect. Shown in lines are the different interaction types between the prodomain and catalytic domains
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-20.0  kJ/mol and -10.0  kJ/mol, respectively. In human 
cathepsins, most of these aromatic residues (except Tyr) 
are substituted with Trp residues with similar bond ener-
gies, an indication of functional significance. A strong 
residue interaction network between the ERFNIN-GNFD 
motifs and other prodomain residues exists in all pro-
teins, confirming the importance of these two motifs in 
maintaining its integrity and structural fold.
A previous mutagenesis study on FP-2 identified 
two salt bridges (Arg185-Glu221 and Glu210-Lys403) 
that are important in the activation of the enzyme [95]. 
From the residue interaction analysis, Arg185 formed a 
stronger salt bridge with Asp216 (− 21.2  kJ/mol) than 
with Glu221 (− 9.5  kJ/mol). To validate these results, 
Asp216 and Glu221 were independently mutated with an 
alanine residue and their interaction energy contribution 
with Arg185 was determined. A complete loss of interac-
tion for Glu221Ala mutation was observed (0.6  kJ/mol) 
while Asp216Ala energy dropped by half to − 12.5  kJ/
mol, an indication that the ionic pair between Arg185 
and these two positions play a critical biological function. 
These two residues are fully conserved in all of the pro-
teins studied here. The second predicted salt bridge by 
Glu210-Lys403 (FP-2 numbering) has high residue varia-
tion across all the proteins. For the charged Glu210 posi-
tion in FP-2, all the other plasmodial proteases and Cat-S 
have a polar residue (Gly) while the other cathepsins have 
a non-polar residue (Ala). Most of the residues in posi-
tion Lys403 (FP-2 numbering) are mainly charged except 
KP-3, BP-2, YP-2 and Cat-K which have a polar residue. 
The energetic contribution from the interactions forming 
this second salt bridge were insignificant in all proteins 
(< − 1.0 kJ/mol). However, PIC interaction results showed 
that position 209 in FP-2 consisted of highly conserved 
positively charged residue (mostly Lysine) across the 
other plasmodial proteases which formed strong ionic 
contacts with Asp398 (fully conserved in all plasmodial 
proteases), an indication that the second salt bridge was 
most likely formed by these residues. In addition, the 
mutagenesis study [95] also identified aromatic–aro-
matic interactions in FP-2 between Phe214 (of the GNFD 
motif ), Trp449 and Trp453 to be equally important in 
the activation of the zymogen forms. These residues were 
conserved in all proteins (except Cat-K and Cat-S) and 
formed strong interactions, an indication that they are of 
functional importance as in FP-2. For Cat-K and Cat-S, 
strong hydrophobic interactions occur between a leucine 
residue in the GNFD motif (Leu78) and Trp302 (Cat-K 
numbering).
A specific aim of this study was to determine the 
responsible residues that confer the prodomain with its 
inhibitory function. To better understand how the inhibi-
tory prodomain per protein interacted with the four 
subsites of these proteins, residue energy based interac-
tion analysis was performed. From residue interaction 
results, only a small portion of the prodomain (~ 22-mer) 
had significant contacts with individual protein subsite 
residues and was therefore responsible for the inhibitory 
effect (Fig.  8). The main residues mediating the inhibi-
tory effect are located on the α3-helix and the down-
stream inter-joining C-terminus prodomain loop region, 
and mostly interact with subsite S2 and S1′ residues via 
hydrophobic interactions and hydrogen bonds (Fig.  8 
and Additional file 6). This may be of significance in the 
development of peptide based inhibitors as previous 
studies have established residues forming these two sub-
sites to be critical for the inhibitory effect and selectivity 
of non-peptide inhibitors [32, 50]. A common interaction 
profile between the prodomain inhibitory segment and 
the various catalytic subsite residues across all the pro-
teins is observed (Fig. 8). For subsite S1, a limited residue 
contact network exists mainly with residues located at 
the α3-helix in all the proteases. There is a hydrophobic 
bond between a highly conserved Tyr226 residue (FP-2 
numbering) in plasmodial proteases and the first position 
of subsite S1 (Figs.  4, 7a). Additional hydrogen bonding 
between highly conserved Lys225 and Asn281 residues 
(FP-2 numbering) occur in the plasmodial proteases. The 
C-terminal end of prodomain segment mainly exhibits 
contacts with S2 and S3 subsites, with human cathepsins 
and rodent plasmodial proteases forming stronger inter-
actions than the human plasmodial counterparts (Fig. 8). 
In plasmodial proteases, a highly conserved Leu229 (FP-2 
numbering) forms a hydrogen bond with subsite S2 fifth 
position (Asn416 [FP-2 numbering]). In all proteins, the 
first three prodomain inhibitory segment amino acids 
(part of the GNFD motif ) form strong hydrophobic con-
tacts with residues at the opening of S1′ subsite (Fig. 8). 
Rodent plasmodial proteases have an additional hydro-
gen bonding network with these residues due to the 
presence of a charged residue at the fifth S1′ position. 
From the interaction energy results, there are no observ-
able contacts between the fourth and seventh residues 
(Ala215 to Thr218 [FP-2 numbering]) of the inhibitory 
segment in the majority of the proteins subsite residues. 
However, a strong hydrogen bonding and hydrophobic 
interaction network is formed by residues located down 
of the eighth residue on the prodomain inhibitory seg-
ment and various catalytic subsite residues in all the pro-
teins. In FP-2, the network is between Ser228, Leu229, 
Arg230 with Leu415, Asn416 (S2), Ile406, Ala400 (S1′) 
and Gly325-326 (S3). Lys233 residue forms very strong 
ionic interactions with Asp477 (S2), a position mainly 
occupied by charged residues only in the human plas-
modial proteases. The side-chain of Ser228 in FP-2 
forms hydrogen bonding with the thiol group of catalytic 
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Cys285. A similar interaction network in all the other 
plasmodial proteases was observed (Additional file  6). 
For the human cathepsins, these interactions seemed to 
be stronger especially with the third subsite S2 position. 
From the interaction fingerprint, residues that are key in 
anchoring and maintaining the stability of the prodomain 
as well as mediating its catalytic domain regulatory effect 
were identified per protein.
Peptide inhibitory effect and selectivity dependent 
on composition and length
Despite their poor chemical properties, peptides remain 
a promising class of enzyme modulators as they are 
chemically diverse, highly specific and relatively safe [96, 
97]. Recently, the identification of antiparasitic peptides 
is gaining momentum and a fully referenced database 
of 863 validated anti-parasite peptides from different 
sources has been established, of which 65% of these have 
anti-malarial properties [98]. Designing peptide based 
inhibitors requires prior understanding of how an 
enzyme recognizes its native peptide substrate then mod-
ifying the resulting interactions. Additionally, hot spot 
residues that regulate protein–protein/domain interac-
tions may provide valuable insights. For FP-2, three pep-
tide studies based on its prodomain-catalytic domain 
interaction network have already been performed. Rizzi 
et al. designed peptidomimetics based on the interaction 
information between cystatin and FP-2 [99]. Although 
this study focussed on FP-2, expansion to the other plas-
modial proteases would have been necessary to provide 
additional information on the broad anti-malarial inhibi-
tory potency of the resulting cystatin mimics. Another 
study by Korde et al. using a synthetic 15-mer oligopep-
tide based on the N-terminal extension of FP-2 partial 
zymogen (LMNNAEHINQFYMFI) showed that it could 
inhibit substrate processing activity of recombinant 
FP-2 in vitro [100]. Although the interaction fingerprint 
results using the partial zymogen complex revealed that 
Fig. 8 A heatmap for residue interaction energies between prodomain inhibitory segment and the catalytic subsite residues per protein. The 
inhibitory segment starts from the conserved Asn residue in the GNFD motif (Fig. 4)
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this terminal extension was not the native inhibitory seg-
ment and was not in any way interacting with any of FP-2 
catalytic domain subsite residues, their results imply that 
a wide array of peptides may inhibit these proteases. Fur-
ther studies to establish the molecular basis of inhibition 
by this peptide would be necessary. Lastly, Pandey et al. 
expressed the whole prodomain of FP-2 together with 
truncated segments and evaluated their inhibitory abil-
ity against a series of papain-family cysteine proteases. 
At the end, they determined that a FP-2 prodomain seg-
ment (Leu127-Asp243) which included the ERFNIN and 
GNFD motifs had a broad inhibitory activity against 
FP-3, BP-2, FP-2, Cat-L, Cat-B and cruzain [101]. Con-
sidering its length and molecular mass, the therapeutic 
potential of this peptide is uncertain.
In the current study, peptides aimed at mimicking the 
inhibitory prodomain segment were designed and tested 
based on the identified prodomain-catalytic domain 
interaction fingerprint (Fig. 8). Initially, a 22-mer peptide 
(peptide 1 = NRFGDLSFEEFKKKYLNLKLFD) based on 
the conservation of the prodomain segments responsible 
for the inhibitory mechanism for all the proteases studied 
was selected for docking against the catalytic domains of 
individual proteins using the CABS-dock webserver 
(Fig. 9). CABS-dock performs blind docking simulations 
to identify the most probable binding site while main-
taining the flexibility of the peptide ligand [89]. The ΔG 
of the top protein-peptide complex model per protein 
was then determined using the PRODIGY server. A por-
tion of this peptide interacted with active pocket residues 
of individual proteins and formed complexes exhibiting 
high binding affinities akin to FP-2/Chagasin X-ray crys-
tal complex [PDB: 2OUL - ΔG − 11.9, Kd= 1.9e–09] 
(Table 4). Despite the high predicted affinity scores with 
peptide 1, no differential binding was observed with the 
human cathepsins. An interaction analysis between the 
peptide and catalytic domain of the various proteins 
revealed that the peptide had numerous intra-chain resi-
due interactions which enhanced dimerization and cycli-
zation (Additional file  7). Additionally, the peptide had 
very strong interactions with most of the subsite residues 
across all the proteins. The peptide’s N-terminus which 
has some of the GNFD motif residues interacted with 
neighbouring residues in the same chain forming a clus-
tered end (Additional file  7), a probable reason why 
strong contacts with residues around subsite S1 and S1′ 
were observed with the N-terminal prodomain inhibitory 
segments. Consequently, it was decided to investigate if a 
shorter peptide lacking these residues would bind differ-
ently without forming the clustering observed with pep-
tide 1. A different set of docking experiments with a 
peptide (peptide 2 = LTYHEFKNKYLSLRSSK) derived 
from the main inhibitory segment of FP-2 was per-
formed. Despite the variation in length, peptide 2 had 
Fig. 9 Sequence alignment of the prodomain inhibitory segment for the plasmodial and human cathepsin proteases studied. Marked sequence 
sections indicate the portions used to design different oligopeptides for docking studies and their conservation as determined by WebLogo server. 
Actual residue numbering per protein is given on the side
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similar results to peptide 1 and lacked a differential bind-
ing affinity profile between the two protein classes. A 
previous in vitro study by Pandey et al, show that a FP-2 
prodomain harbouring peptide 2 segment exhibited simi-
lar broad inhibitory activity on cruzain, Cat-B, Cat-L, 
FP-2, FP-3 and BP-2 [101]. However, from the energy 
interaction profiles, a large portion of the tested prodo-
main including the ERFNIN/GNFD motifs is mainly 
involved in anchoring it to the catalytic domain. Thus, 
the main inhibitory segment is much shorter and down-
stream of the GNFD motif. Peptide 2-YP-2 complex had 
the strongest binding association (− 14.3 kcal/mol) while 
VP-2 had the lowest (− 10.1  kcal/mol). Both peptide 1 
and 2 interacted with majority of the subsite residues in 
all the proteins studied. With the already tested peptides 
exhibiting unselective high affinity binding on both 
human cathepsins and plasmodial proteases, additional 
docking experiments were performed with a different 
peptide derived from the most conserved residues in the 
same inhibitory segment as peptide2 from all proteases 
studied (peptide 3 = MTFEEFKQKYLTLKSKD). In some 
positions within the prodomain inhibitory segments 
across the plasmodial proteases, high residue variations 
were observed and there was no consensus about which 
residue to include in the peptide. So the physicochemical 
properties (polar, charged, non-polar, and hydrophobic) 
of the residues in positions exhibiting significant varia-
tion were taken into account. In addition, residues show-
ing stronger interactions with the catalytic subsite 
residues were given preference. From the affinity results, 
the ΔG between peptide 3 and plasmodial proteases was 
significantly lower in most plasmodial proteases than 
with the earlier peptides. From interaction analysis, sub-
site S1 and S1′ had reduced interaction contacts as com-
pared with the previous peptides studied. However, 
Cat-K and Cat-L had similar binding affinity values with 
peptide 1 and 2. Guided by the residue interaction profile 
of prodomain residues with subsite residues (Fig.  8), a 
fourth peptide (peptide 4 = EFKKKYLTLK) composed of 
the most conserved amino acids around α3-helix of the 
inhibitory segment of all plasmodial proteases was evalu-
ated. A similar trend of non-selectivity was observed as 
with peptide 1, though with lower binding affinity except 
in Cat-K. From the binding mode analysis, the peptide 
had a slightly different pose on Cat-K and had interac-
tions with subsite S2 and S1′ residues which were absent 
in the other proteins. This may likely explain the reduced 
binding affinities across the proteins. A fifth peptide, sim-
ilar to peptide 4 except for its length, (EFKKKYLTLK-
SKD) was also evaluated. The residues in this peptide 
showed some conservation in the plasmodial proteases 
and had significant differences to the human cathepsins. 
Interestingly, it bound more strongly to all plasmodial 
proteases compared to the human cathepsins (Table  4). 
From interaction analysis, a differential peptide-catalytic 
subsite bonding network was observed between the plas-
modial and human cathepsin proteins (Fig.  10 and 
Table 5). In addition, the human plasmodial proteins had 
stronger interactions compared to the rodent homologs. 
The peptide’s N-terminus interacted with the subsite res-
idues between subsite S1 and S1′. A strong hydrogen 
bond between the peptide’s third basic Lys residue and 
Table 4 Amino acid sequences of  proposed peptides, their predicted binding affinity values (ΔG—kcalmol−1) 
and dissociation constant  (Kd) with individual catalytic domains of the different proteins studied
Peptide  1NRFGDLSFEEFKKKYLNLKLFD,  2LTYHEFKNKYLSLRSSK,  3MTFEEFKQKYLTLKSKD,  4EFKKKYLTLK,  5EFKKKYLTLKSKD
Protein Peptide
1 2 3 4 5
ΔG Kd (M) ΔG Kd (M) ΔG Kd (M) ΔG Kd (M) ΔG Kd (M)
FP-2 − 11.8 2.2E−09 − 11.2 8.4E−09 − 8.1 1.2E−06 − 9 2.7E−07 − 11.4 4.4E−09
FP-3 − 12.2 1.2E−09 − 10.5 2.0E−08 − 9.6 9.4E−08 − 9.7 7.8E−08 − 12.3 8.8E−10
VP-2 − 11.0 8.3E−09 − 10.1 3.8E−08 − 12.3 8.8E−10 − 9.0 2.7E−07 − 10.9 1.1E−08
VP-3 − 11.7 2.7E−09 − 11.0 8.3E−09 − 9.9 5.7E−08 − 9.2 1.7E−07 − 11.8 2.1E−09
KP-2 − 12.7 4.7E−10 − 11.8 2.1E−09 − 6.7 1.3E−05 − 8.1 1.2E−06 − 10.6 1.8E−08
KP-3 − 11.8 2.1E−09 − 12.7 5.2E−10 − 9.3 1.4E−07 − 9.2 1.9E−07 − 12.7 5.2E−10
BP-2 − 11.5 3.7E−09 − 12.2 1.2E−09 − 10.9 9.9E−09 − 7.9 1.7E−06 − 11.7 2.7E−09
CP-2 − 11.9 2.2E−09 − 11.7 2.7E−09 − 8.7 3.9E−07 − 8.3 1.1E−07 − 12.7 4.7E−10
YP-2 − 11.7 2.7E−09 − 14.3 5.5E−11 − 12.4 7.9E−10 − 10.4 2.5E−08 − 9.3 1.5E−07
Cat-K − 13.9 6.3E−11 − 11.5 3.5E−09 − 11.9 2.0E−09 − 11.4 4.2E−09 − 8.3 1.1E−07
Cat-L − 12.2 1.0E−09 − 11.8 5.1E−09 − 12.3 9.7E−10 − 10.2 3.5E−08 − 8.7 9.2E−07
Cat-S − 10.4 2.4E−09 − 11.5 3.5E−09 − 12.4 7.7E−10 − 9.9 5.2E−08 − 8.6 4.8E−07
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the highly conserved acidic Glu residue of the first posi-
tion of subsite 1 was observed in all the proteins. The 
main interactions (number and strength) occurred in S2 
and S1′. Previously, a high residue variation between the 
plasmodial and human proteases was established in both 
S2 and S1′ subsites [50]. The observed interaction pattern 
by the peptide and the proteins could be the most proba-
ble factor for the differential affinities between the plas-
modial and human cathepsins (Table  4). In most of the 
plasmodial proteases, peptide 5 bound with almost the 
same affinity as that of chagasin and FP-2 (− 11.9  kcal/
mol). From the prodomain-catalytic interaction analysis 
(Table  5 and Fig.  10), the C-terminal end in peptide 5 
interacts with the last position of S2 which consists of a 
charged residue (only in human plasmodial proteases) 
forming a strong ionic interaction (< − 15 kJ/mol) as well 
as other non-subsite residues thus forming a stronger 
complex. In most plasmodial proteases, peptide 5 formed 
multiple hydrogen bonds especially with S2 and S1′ sub-
site residues. Besides this information being important in 
the design of strong peptide-based inhibitors, the S2 and 
S1′ residues unique to the plasmodial cysteine proteases 
with a propensity of forming strong (hydrogen and 
hydrophobic) interactions may also be targeted in design-
ing non-peptide inhibitors using CADD. Similarly, the 
side chains of the prodomain residues establishing these 
interactions may be conjugated with other compounds to 
form novel peptidomimetic derivatives with strong inhib-
itory potencies against the plasmodial cysteine proteases. 
Binding poses of peptide 5 and the different proteins 
showed that the peptide fitted within the active pocket 
groove and also made contacts with additional non-sub-
site residues (Fig. 11 and Table 5). Docking studies with 
previously modelled catalytic domains gave results 
Fig. 10 A heatmap for residue interaction energies between peptide 5 and the catalytic subsite residues per protein
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Table 5 Peptide 5-catalytic domain residue interaction fingerprint
Italics are residues forming hydrogen bonds with the peptide
Protein Subsite Non‑subsite residues
S1 S2 S3 S1′
FP-2 Q279, C282, G283, C323 L327, I328, S392, L415, 
N416, A418, D477
N320, G325, G326 V395, S396, A400, H417, 
A418, N447, W449
K280, W286, R470, C285
FP-3 Q287, C290, G291, Y332 Y335, S400, P423, A426, 
E485
K327, N328 A402, A403, S404, A408, 
N424, H425, N455, W457
L289, C293, W294, N338
VP-2 Q282, G286, Y327 F330, I331, P418, N419, 
A421
Q322, N323, G328, G329 I396, A397, V398, A403, 
H420, N451
D282, F331, P332, Y351, 
E367, F389
VP-3 Q288, C291, G292, C332, 
D333
N336, I337, S401, P424, 
N425
G334, G335, N329 I402, C403, A404, N405, 
H426, W458
D287, K289, C294, D406, 
S423, S457, G459, K458, 
W462
KP-2 Q288, C291, G292, C332, 
D333
L336, I337, S401, P424, 
N425, A427, E486
N329, G333, G334 N403, A404, N405, T409, 
H426, N456, W458
K289, N290, A293, C294, 
W295, E382, N405, 
D406, S457
KP-3 Q274, C277, G278, C318, 
D319
F322, N387, T410, N411, 
E472
Q314, N3145, N316, G320, 
G321
I388, A389, V390, S391, 
A395, N442, W444
G275, S279, C280, P324, 
R325, E368, N387, 
D392, T409
BP-2 Q264, A268, C308, E309 I312, A377, A400, N401, 
A403
N304, N305, F306, G311 V378, G379, D381, H402, 
N432, W434
K266, A272, P314, Y334, 
E349, A367, I376
CP-2 Q267, C270, A271, E312 I315, L316, A380, A303, 
N404, A406
N307, N308, D309, G314 V381, G382, A383, S384, 
H405, N437
K265, W274, Q306, P337, 
K351
YP-2 C271, A272, D313 I316, L317, A381, A404, 
N405, A407
N308, N309, F310, G314 V382, G383, V384, A385, 
H406, N438
Q269, W275, F310, E353, 
I380
Cat-K C136, G137 Y181, M182, A248, L274, 
N275, A277
G179 D250, A251, S252, H276 C139, W140, F186, Y224, 
F256, W302, E226
Cat-L C135, N179 L182, A248, D275, G277 N175 I249, A251, L257, H276 P172, G224, A234, I263
Cat-S C134, N179 F182, G249, V274, N275, 
F323
N175, K176, G180 R253, F258, W298 Y173, Y225, E227, P229, 
Y230
Fig. 11 Peptide 5 binding mode with catalytic domain of various proteins (Red = S1, Blue = S2, Green = S3 and Cyan = S1′)
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consistent with the current models. From the motif anal-
ysis (Fig.  6), a large proportion of peptide 5 was repre-
sented in motif M6. Despite the functional annotation of 
motif M4 indicating it as the cathepsin propeptide inhibi-
tor domain, a majority of its residues were predominantly 
involved in anchoring the prodomain. Taken together, 
the current study is the first to identify the most likely 
prodomain segment involved in regulation of cysteine 
proteases, and to apply information based approaches to 
propose a peptide with differential binding on both 
human and plasmodial proteases.
Conclusion
The current study aimed to characterize the differences 
between P. falciparum falcipains and their plasmodial 
and human homologs, especially where the prodomain 
interacts with the catalytic domain, in order to iden-
tify key residues which could be useful in anti-malarial 
drug development approaches. This was done at both 
sequence and structure level. Through homology model-
ling, near native 3D partial zymogen complexes of both 
plasmodial and human proteases were obtained. This 
allowed structural characterization, thus deciphering 
how these segments confer their inhibitory mechanism 
endogenously. The main prodomain residues mediat-
ing the inhibitory effect were located in the α3-helix and 
the inter-joining loop region, and mostly interacted with 
subsite S2 and S1′ residues. Previous studies showed that 
residues forming these two subsites are critical in inhibi-
tor design as they differ from human cathepsins [50, 57]. 
Hence, putting all the analysis together, with a continu-
ous prodomain epitope mimicking strategy, a peptide 
(peptide 5) which bound selectively, i.e. more strongly on 
plasmodial proteases than the human ones was designed. 
The present approach offers a starting point which could 
lead to the establishment of novel anti-malarial peptide 
drugs aimed at mimicking the natural plasmodial pro-
tease regulatory mechanism. Despite protein-peptide 
docking being a complex modelling problem owing to 
the significant conformational changes between the pep-
tide ligand and receptor and limited availability of accu-
rate docking scoring functions, CABS-dock engine was 
able to determine the binding pockets of the studied 
proteins accurately in virtually all docking experiments. 
Accessibility of parasite infected erythrocytes by macro-
molecules remains a major concern for the development 
of peptide based anti-malarial inhibitors. A study by 
Farias et al. using fluorescent peptides revealed that pep-
tides with molecular weight up to 3146  Da can perme-
ate into the blood stage parasites [102]. All the peptides 
determined had a mass of below 2753  Da, with peptide 
5 having 1613 Da, an indication that it would readily be 
available inside the parasites. Korde et al. demonstrated 
that a synthetic 15-mer oligopeptide of mass 1885  Da 
could localize into the intracellular compartments of 
trophozoites and schizonts inhibiting FP-2 activity [100]. 
Additional chemical optimization of peptide 5 could pro-
vide improved derivatives with potency and selectivity 
together with physicochemical properties that enhance 
bioavailability and stability. Bioavailability remains a 
major challenge in the application of peptides as anti-
malarial drugs despite their selectivity and potency. To 
overcome this barrier, nanocarrier based technology 
aimed at increasing the concentration of peptide and low 
soluble drugs in the desired tissues and cells is currently 
being evaluated with promising results attained so far 
[71]. Thus, the full potential of peptide based anti-malar-
ial drugs may be realized in the near future.
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